Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ENZON PHARMACEUTICALS, INC. | c67808_ex99-1.htm |
|
UNITED
STATES |
||
|
FORM 8-K |
||
|
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
||
|
Date of Report (Date of earliest event reported): December 8, 2011 |
||
|
ENZON PHARMACEUTICALS, INC. |
||
|
Delaware |
0-12957 (Commission File Number) |
22-2372868 |
20
Kingsbridge Road, Piscataway, New Jersey |
08854 |
(732) 980-4500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01 Other Events.
On December 8, 2011, Enzon Pharmaceuticals, Inc. issued a press release announcing that it presented data from a Phase II, open-label study of PEG-SN38 (EZN-2208) in patients with previously treated metastatic breast cancer.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
|
Exhibit No.
|
Description
|
|
99.1 |
Press Release of Enzon Pharmaceuticals, Inc. dated December 8, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENZON PHARMACEUTICALS, INC. | |||
| (Registrant) | |||
| Date: December 8, 2011 | By: | /s/ Andrew Rackear | |
| Name: Andrew Rackear | |||
| Title: Vice President and General Counsel | |||
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
99.1 |
Press Release of Enzon Pharmaceuticals, Inc. dated December 8, 2011 |